ArticleFrontiers in oncology2026
Efficacy and safety of deep hyperthermia combined with tislelizumab and chemotherapy in the treatment of advanced squamous non-small-cell lung cancer: a single-center retrospective study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the efficacy and safety of deep hyperthermia combined with tislelizumab and chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC). Methods: A total of 100 patients with advanced squamous NSCLC undergoing initial treatment at our hospital between January 2021 and early January 2023 were enrolled. Patients were categorized into an experimental group (n=50) and a control group (n=50). The control group received tislelizumab plus chemotherapy, while the experimental group received deep hyperthermia combined with tislelizumab and chemotherapy. The main objective was objective response rate (ORR). Secondary endpoints encompassed overall survival (OS), progression-free survival (PFS), disease control rate (DCR), and safety. Results: ORR in the experimental group was 66.0% (33/50), with a DCR of 86.0% (43/50). The ORR and DCR in the control group were 46.0% (23/50) and 84.0% (42/50), respectively. ORR in the experimental group was higher than that in the control group( Conclusion: The combination of deep hyperthermia, tislelizumab, and chemotherapy as an initial therapy for advanced squamous non-small-cell lung cancer (NSCLC) is safe and effective and should be tested on a larger scale in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.